Axonyx Closes Enrollment in Pivotal Phase III Trial with Phenserine for Alzheimer's Disease; Company Provides Update on Beta Amyloid Phase IIB Trial.
Linked as:
Extract
Axonyx Closes Enrollment in Pivotal Phase III Trial with Phenserine for Alzheimer's Disease; Company Provides Update on Beta Amyloid Phase IIB Trial.
NEW YORK -- Axonyx Inc. (NASDAQ:AXYX) today announced that it has completed enrollment in the first of its two on-going Phase III clinical studies evaluating Phenserine in patients with mild to moderate Alzheimer's disease. Following six...
See the full content of this document
Sponsored links
